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Abstract In the current study we aimed to gain insight into
epithelial-mesenchymal cross-talk and progenitor compart-
ment modulation during doxorubicin (DOX)-induced mu-
cositis in mice. Intestinal segments were collected on various
days after DOX treatment. DOX-induced damage at day 1–2
was characterized by increased epithelial proliferation and
apoptosis and a decrease in the expression of epithelial dif-
ferentiation markers. Concurrently, T-cell factor-4 (TCF4)
levels increased and the epithelial differentiation enhanc-
ing factor, bone morphogenic protein-4 (BMP4), decreased.
During severe damage (day 3), BMP4 levels were signifi-
cantly increased, which inversely correlated with epithelial
proliferation. At the same time, the expression of the epithe-
lial differentiation markers was increasing again. At day 7,
BMP4 levels were down-regulated, while the levels of the
epithelial differentiation markers and TCF4 were normalized
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again. These data suggest that in response to DOX-induced
damage, BMP4 and TCF4 are modulated in such a way that
homeostasis of the progenitor compartment is partly pre-
served.
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Introduction
The highly proliferating small intestine is very susceptible
to chemotherapy-induced damage [31, 47]. This side effect,
often referred to as mucositis, is very painful and can be life
threatening due to the enhanced risk of bacterial transloca-
tion caused by loss of epithelial barrier function. Each year,
around 500,000 patients worldwide suffer from this side ef-
fect [7] for which there is still no definitive prophylaxis or
treatment.
Drug-induced damage to the highly proliferating stem
cells and progenitors located in the crypts of Lieberku¨hn
showed that different classes of cytostatic drugs affect ep-
ithelial crypt cells of different topographical and hierarchical
status [12, 13, 24]. Methotrexate (MTX), 5-fluorouracil and
vincristine for example, induce damage high in the prolifera-
tive compartment at crypt position 9–11. Damage induced by
MTX is well characterized and shows severe morphological
changes characterized by epithelial flattening, villus-atrophy,
and specific de-differentiation of enterocytes. The last one
is indicated by a decreased expression of the enterocyte-
specific enzymes but a maintained expression of goblet and
Paneth cell-specific genes [29, 38, 41, 45, 46]. Doxorubicin
(DOX) is a cytostatic drug that also frequently causes severe
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mucositis. However, DOX-induced damage is not well char-
acterized [28]. DOX preferentially attacks cells at crypt posi-
tion 4–6, which is just above or at the same level as the intesti-
nal stem cells [12, 32]. DOX is therefore thought to induce
more severe damage, especially to the proliferating compart-
ment at the bottom of the crypts, as for example MTX. In
clinical practice, DOX is often used in treatment of solid tu-
mors, leukemia, and lymphomas in both adult and childhood
cancer patients [16, 18, 21, 28]. Recent studies revealed a
dynamic cascade of events leading to chemotherapy-induced
mucositis [35]. Not only are the specialized epithelial cells
affected by cytostatic-drug treatment, but also the underlying
submucosal connective tissue. Under normal physiological
circumstances, the epithelium maintains a cross-talk with the
mesenchyme. Epithelial-mesenchymal interactions are crit-
ical for the normal morphogenesis and maintenance of the
crypt-villus axis [15, 23].
Bone morphogenic protein (BMP)- and Wnt-signaling
pathways are two of the main pathways involved in em-
bryonic and adult intestinal development [5, 33]. BMPs are
morphogenes that constitute a large group of structurally
and functionally related proteins of the TGF-beta superfam-
ily. BMP signaling pathways have a key role in organo-
genesis [2, 37], gastrointestinal development and intestinal
homeostasis in adults [8–11, 14, 27]. After intestinal devel-
opment, BMP4 is exclusively expressed in the intravillus
and intracrypt mesenchymal cells, including those adjacent
to the intestinal stem cells [8, 10]. Paracrine BMP signal-
ing occurs specifically in the villus from the mesenchyme
to the adjacent epithelium [8], suggesting involvement in
epithelial-mesenchymal interactions as a mesenchymal sig-
naling molecule.
The Wnt-signaling pathway also has been implicated
in the regulation of the intestinal epithelial prolifera-
tion/differentiation balance in vitro [43]. In the intestine
of mice deficient for transcription factor TCF4, the main
Wnt pathway transcription factor in the intestinal epithe-
lium, loss of proliferative compartments and epithelial cell
differentiation are found [17]. Interestingly, the BMP- and
Wnt pathways appear to be linked, as was shown by the fact
that BMP signaling suppresses Wnt signaling to ensure a
balanced control of stem cell proliferation and subsequent
epithelial differentiation [8, 10].
The objective of this study was to develop an experimen-
tal mucositis mouse model to characterize DOX-induced in-
testinal damage and subsequent repair. In addition, we aimed
to correlate the alterations in morphology, epithelial home-
ostasis, and gene expression with changes in BMP4 and
TCF4 expression. This, in order to gain insight into pos-
sible modulation of the epithelial-mesenchymal cross-talk
and progenitor compartment during chemotherapy-induced
intestinal damage and regeneration.
Materials and methods
Animals
Animal experiments were performed with permission of the
Animal Ethics Committee of the Erasmus MC-Sophia. Upon
arrival at our institute, 10-week-old male BALB/c mice (Har-
lan, Horst, The Netherlands) were housed individually dur-
ing the whole experiment in micro-isolator cages under spe-
cific pathogen-free conditions with free access to a standard
palletized diet (Hope farms, Woerden, The Netherlands) and
water. After 1 week of adjustment to the new environment,
the mice were divided into three groups and injected in-
travenously with doxorubicin (DOX) (Doxorubicin, Pharma
Chemie, Haarlem, The Netherlands) on two subsequent days.
At day − 1 and 0, the first group of mice was injected with
a low dose of DOX of 6 and 4 mg/kg (low dose) respec-
tively, a second group was injected with a medium dose of 8
and 5 mg/kg (medium dose) and a third group was injected
with a high dose of 10 and 6 mg/kg (high dose). Controls
were given equivalent volumes of 0.9% NaCl. Mice in the
low- and high-dose group were sacrificed at day 1, 2, 3 and
7 after the final DOX injection; mice in the medium dose
group were only sacrificed at day 3 and 7. One hour be-
fore sacrifice, the mice were injected with 120 µl 10 mg/ml
5- Bromo-2’deoxyUridine (BrdU) (Sigma-Aldrich, Zwijn-
drecht, The Netherlands), an uridine analog, to locate the
proliferating cells. Per time point 4–6 DOX-treated animals
and 2–4 control animals were sacrificed. Segments of mid-
jejunum were collected and either processed immediately
for histological analyses or snap-frozen in liquid nitrogen
for storage at − 80◦C and subsequent protein isolation.
Histochemistry
Five-millimeter segments of mid-jejunum were fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS), dehy-
drated and embedded in Paraplast Plus (Sherwood Medical,
Den Bosch, The Netherlands) as previously described [45].
Four µm sections were routinely stained with hematoxylin
(Vector Laboratories, Burlingame, CA) and eosin (Sigma-
Aldrich) to study morphological alterations of the crypts
and villi. Immunohistochemistry was performed as described
previously [45] with some minor modifications. The sections
for BrdU staining required an extra adjustment to this pro-
tocol of HCL incubation, washing with borate buffer, and
pepsin treatment as described before [34]. In short, the sec-
tions were blocked as described and incubated overnight with
the following antibodies diluted in PBS: to visualize BrdU
incorporation, mouse monoclonal anti-BrdU (1:250, Roche
Applied Sciences, Indianapolis, IN) was used, as an ente-
rocyte marker rabbit polyclonal anti-rat Sucrase-Isomaltase
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(SI) (1:9000 in PBS, kindly provided by Dr. K.Y. Yeh [49])
was used and as a goblet cell-specific marker rabbit poly-
clonal anti-rat trefoil factor family (TFF3: 1:3000, kindly
provided by Prof. Dr. D.K. Podolsky) was used. Furthermore,
BMP expression was visualized with anti-BMP4 (1:100,
R&D Systems, Abingdon, UK). Immunoreactions were de-
tected using Vectastain ABC Elite Kit (Vector Laboratories,
Burlingame, CA) and 3,3′-diaminobenzidine tetrahydrochlo-
ride (Sigma-Aldrich, Zwijndrecht, The Netherlands).
Crypt and -villus length
Longitudinal sections of crypts and their corresponding villi
were selected so that the base (marked by Paneth cells),
middle and top of the crypt were all in the plane of section
and thus well orientated. The depth of ten crypts and the
length of ten villi were measured on three slides per animal,
four animals per time point, with the use of a Nikon Eclipse
E800 microscope and IM 500 software.
Protein dot blotting
The expression of enterocyte markers was detected and quan-
tified as described previously [46]. Briefly, 5-mm segments
of the mid-jejunum were homogenized and protein con-
centrations were measured using the BCA Protein Assay
Reagent (Pierce, Rockford, IL) and 50 µg protein of each ho-
mogenate was dot-blotted on nitrocellulose (Protran BA83,
0.2 µm; Schleicher & Schuell, Dassel, Germany). Hereafter,
blots were blocked for 1 h with blocking buffer containing
50 mM Tris, pH 7.8, 5% (wt/vol) nonfat dry milk powder
(Campina Melkunie, Eindhoven, The Netherlands), 2 mM
CaCl2, 0.05% (vol/vol) Nonidet P40 (BDH, Brunschwig
Chemie, Amsterdam, The Netherlands) and 0.01% Antifoam
B (Sigma-Aldrich). Blots were incubated overnight at 4◦C
with rabbit polyclonal anti-rat SI (1:1000 [49]), and rab-
bit polyclonal anti-rat trefoil factor family (TFF3: 1:1500)
diluted in blocking buffer. After washing with blocking,
the buffer blots were incubated with 125I-labeled protein
A (specific activity 30 mCi/mg, Amersham Biosciences,
Roosendaal, The Netherlands) for 2 h at room temperature.
Specific binding of 125I-labeled protein A to the enterocyte
marker antibodies was measured using PhosphorImager de-
tection. The elicited signal was quantified by ImageQuant
software (Molecular Dynamics, B&L systems, Zoetermeer,
The Netherlands) and the expression of TFF3 and SI was
expressed per 50 µg protein of tissue. Average expression
levels of TFF3 and SI in the mid-jejunum were calculated
per mouse, followed by calculation of the mean expression
of TFF3 and SI per time point studied. Subsequently, the
average expression of TFF3 and SI of control mice was set
at 100%. The specificity of the above-described antibodies
was previously confirmed by Western-blot analysis [46].
Western-blot analysis
The same protein homogenate was used as described for
protein dot blot analysis. Twenty µg of protein was loaded
per lane and run on a 12.5% SDS-PAGE. The separated pro-
teins were transferred to nitrocellulose membranes (Protran
BA83, 0.2 µm) and blocked for 1 h at room temperature in
blocking buffer as described above. The blots were incubated
overnight at 4◦C with primary antibodies diluted in blocking
buffer: mouse monoclonal anti-human PCNA, clone PC10
(1:250, Novo Castra Laboratories, Newcastle upon Tyne,
UK) and mouse monoclonal anti-human BMP4, clone 3H2
(1:100), (Novocastra Laboratories, Newcastle upon Tyne,
UK), rabbit polyclonal anti-human cleaved Caspase-3 an-
tibody (1:1000, Cell Signaling, Beverly, MA), and mouse
monoclonal anti-human TCF-4, clone 6H5-3 (1:250, Up-
state, Waltham, MA). After washing with PBS, 0.2% Tween-
20 blots bound antibodies were revealed using HRP conju-
gated goat anti-mouse or rabbit anti-goat secondary antibod-
ies (1:1000) and SuperSignal West Femto Luminol Enhancer
kit (Pierce, Rockford, IL). The signal was detected and quan-
tified by the ChemiGenius gel documentation system (Syn-
gene, Cambridge, UK) and the expression of the specific
proteins analyzed was expressed per 20 µg protein of tis-
sue. Average expression levels of PCNA, BMP4, TCF4, and
caspase-3 in the mid-jejunum were calculated per mouse,
followed by calculation of the mean expression of these
specific proteins per time point studied. Subsequently, the
average expression of PCNA, BMP4, TCF4, and caspase-3
in control mice was set at 100%.
Statistical analysis
Changes in protein expression levels during damage and
regeneration were statistically analyzed using the Kruskal-
Wallis H-test and the Mann-Whitney U-test. A p < 0.05 was
considered statistically significant. Data are presented as the
mean ± standard error of the mean (SEM).
Results
Dose-response analysis of DOX-induced mucositis in
an experimental mouse model
To optimize the dose of DOX necessary to induce severe in-
testinal damage (i.e., villus atrophy, crypt loss and flattening
of the epithelial cells) a dose-response curve was performed.
Thereto, mice were divided in three treatment groups: low
dose, medium dose, and high dose (see Materials and meth-
ods, section Animals for details). In the high-dose treatment
group, two of the six mice died at day 4. Necropsy showed an
excess of fluid in the abdominal cavity of unknown source.
Because of the elapsed time after death, morphological eval-
uation could not be performed.
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Morphological analysis of the low-dose treatment group
at days 1 and 2 (data not shown), revealed only a slight in-
crease in crypt length, which became more pronounced at
day 3 (Fig. 1B). An increase in crypt length was also seen
in the medium dose group at day 3. (Note the medium-dose
treatment group was not studied at days 1 and 2). No other
morphological changes were seen in the low dose- (days
1–3) and medium-dose group (day 3). In contrast, in the
high-dose treatment group we did see severe morphological
damage (Fig. 1D–F). Specifically, severe villus atrophy, crypt
lengthening, crypt loss, perturbation of crypt arrangement,
flattening of crypt and villus epithelium and inflammation
were observed at day 3 (Fig. 1F). Moreover, the latter mor-
phological damage was already seen, although in a milder
degree, at days 1 and 2 after the high-dose DOX treatment
(Fig. 1D, day 1 and Fig. 1E, day 2). At day 7, the intestinal
morphology was completely restored in the low-dose and
medium-dose group (data not shown), but was still affected
in the high-dose group. As in the latter group, the crypt ep-
ithelium still showed signs of regeneration, like new crypt
formation and less epithelial flattening (Fig. 1G).
Quantitative analysis of crypt and villus length
To quantify the amount of morphological damage induced by
the different doses of DOX, the length of the crypts and villi
were measured (Fig. 1H–I). In the high-dose group, but not in
the low-dose or medium-dose group, a significant increase in
crypt length was already observed at day 2 (data not shown).
At day 3 the crypt length was significantly increased in each
treatment group compared to the control group (Fig. 1H). By
day 7, the length of the crypts had returned to control levels
in the low-dose and medium-dose group, but were still in-
creased in the high-dose group. This increase in crypt length,
however, showed a trend towards normal levels because the
crypt length at day 3 was 41% above control level but at day
7 this was still only 13% above control level. The length of
the villi did not change in the low-dose or the medium-dose
treatment group on each day investigated. However, in the
high-dose treatment group the length of the villi were sig-
nificantly decreased on days 1–3 and 7 (Fig. 1H, day 3 and
1I, day 7). Because severe intestinal mucositis (day 3) and
morphological regeneration (day 7) were seen only in the
high-dose treatment group, we continued our studies with
the high-dose DOX treatment model.
Effects of high-dose DOX treatment on
enterocyte-specific gene expression
To gain insight into the functional capacity of the intesti-
nal epithelium after DOX treatment, a sucrase-isomaltase
(SI) immunohistochemical staining was performed. SI is an
enterocyte-specific disaccharidase responsible for sucrose
degradation. SI is expressed in the brush border of differ-
entiated villus enterocytes directly after weaning [42] and
is considered an intestinal epithelial differentiation marker.
At day 1 and 2 after DOX treatment SI was expressed in
the brush border of enterocytes along the entire villi, com-
parable to the control epithelium (Fig. 2A, control; B, day
1; C, day 2). At day 3, SI staining showed a patchy pattern
with weak staining on less affected parts of the epithelium
and even absence of staining on severely damaged epithelial
parts of the sections (Fig. 2D). At day 7, during the regenera-
tive phase, the SI staining pattern was comparable to control
again (Fig. 2E).
To quantify SI protein expression, protein dot-blot anal-
yses were performed using SI-specific antibodies (Fig. 2F).
The SI protein expression level at day 1 was similar to the
control situation. At day 2, SI expression levels were sig-
nificantly decreased and remained significantly decreased at
day 3. At day 7, the SI expression levels regained to control
levels.
Effects of DOX treatment on goblet cell-specific
gene expression
Goblet cell-specific gene expression after high-dose DOX
treatment was analyzed by the expression of trefoil factor
family 3 (TFF3). TFF3 is a bioactive peptide, produced and
secreted by goblet cells, that is involved in epithelial pro-
tection and repair [6, 22]. Immunohistochemical staining of
TFF3 showed TFF3 expression by goblet cells in crypts and
villi of the jejunum (Fig. 3). At day 1, the TFF3 staining
was not visibly altered compared to the control situation
(Fig. 3B). At day 2, the immunohistochemical detection of
TFF3 decreased visibly, especially in the goblet cells lo-
calized in the crypts and lower part of the villi where TFF3
protein could hardly be detected/was absent (Fig. 3C). At day
3, during most severe morphological damage, TFF3 staining
by goblet cells in the crypt was reconstituted (Fig. 3D). Day
7 showed complete regeneration of TFF3 (Fig. 3E).
Subsequently, a protein dot-blot analysis was performed
(Fig. 3F) using TFF3-specific antibodies to quantify TFF3
levels. At day 1, the TFF3 expression was already signifi-
cantly decreased to 50% of control level and maintained at
this low level at day 2. At day 3, concomitant with the most
severe morphological damage, TFF3 expression returned to
control level. TFF3 protein expression was again comparable
to control situation at day 7.
Effect of high-dose DOX treatment
on epithelial proliferation
Localization of proliferation was studied by immunohisto-
chemical detection of incorporated BrdU (Fig. 4). In con-
trols (Fig. 4A) BrdU was mainly localized in cells from the
Springer
1818 Dig Dis Sci (2007) 52:1814–1825
Fig. 1 Morphology of the murine small intestine after low, medium-
or high-dose DOX treatment. Morphology of the jejunum of a con-
trol mouse (A), at day 3 after low-dose DOX (B) and at day 3 after
medium-dose DOX (C), both were mildly affected by DOX treatment.
Morphology of the jejunum at day 1 (D) and day 2 (E) after high-dose
DOX treatment, which appeared progressively affected and severely de-
teriorated at day 3 (E). At day 7, the regenerative phase, the intestinal
morphology of the mice in the low- and medium-dose group was com-
pletely restored to control situation (data not shown). The morphology
at day 7 of the mice treated in the high-dose group was regenerating,
showing new crypt formation but still villus atrophy. These photographs
are representative examples of a group of four animals per time-point.
To quantify the effect of these different doses of DOX treatment, crypt
and villus lengths were measured. Crypt and villus lengths of control
mice were set at 100%. At day 3 (A), the length of the crypts in all
three DOX treatment groups was significantly increased in compari-
son to the control group. Villus length in the low- and medium-dose
group remained at control level. The length of the villi of the high-dose
group decreased significantly, indicating significant villus atrophy af-
ter high-dose DOX treatment. At day 7 (B) crypt and villus lengths
of the low- and medium-dose DOX treatment groups showed com-
plete restoration. The crypts of the high-dose treatment group were
still significantly longer, but this increase in crypt length was declining
compared to day 3 (day 3 41%, day 7 13%). The length of the villi was
still significantly decreased at day 7, showing no signs of regeneration.
∗P < 0.05 versus control. The bars are expressed in mean + SEM
bottom of the crypt up to three quarter of the crypt length.
At day 1 and 2 the proliferative zone broadened and progres-
sively moved upwards to the crypt-villus junction. At day
3, during severe morphological damage, BrdU-positive cells
formed a scattered pattern throughout the remaining crypt
structures of the small intestine. In the regenerative phase, at
day 7 BrdU-positive cells were located in the lower part of
the crypts again.
The changes in proliferation induced by DOX were quan-
tified by Western-blot analysis of PCNA protein expression
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Fig. 2 Effect of high-dose DOX treatment on the enterocyte-specific
SI expression in the small intestinal epithelium. SI expression of the
jejunum of a control mouse (A), at day 1 (B) and at day 2 (C). The
brush border staining at day 1 and 2 is comparable to control situa-
tion. At day 3 (D), SI staining showed a patchy pattern; some parts
of the brush border showed SI expression, on some other parts of the
brush border SI expression was absent (→). SI expression at day 7 (E)
showed complete regeneration, and was equal to the control situation.
SI protein expression levels were analyzed by dot-blot technique and
the SI expression of control mice was set at 100% (F). The expression
of SI remained stable at day 1, but decreased significantly at day 2 and
3. During the regenerative phase, at day 7, the SI expression reached
control level again. ∗P < 0.05 day 2 and 3 versus control. The bars are
expressed in mean + SEM
[4, 40] using a specific monoclonal PCNA antibody. PCNA
protein expression after MTX treatment (Fig. 4F, G) showed
a trend of increased expression at days 1. At day 2, this
increased expression was significant compared to control
levels, indicating that high DOX treatment did not induce
an arrest in proliferation at day 1 and 2. At day 3, PCNA
expression was decreased to around 20% of the normal level
and was still 50% of control level at day 7. The latter data in-
dicate that the inhibition of epithelial proliferation sustained
during the regenerative phase. Overall, the PCNA levels cor-
related with the immunohistochemical data (Figs. 4A–E vs.
4G)
Effect of high-dose DOX treatment
on enterocyte apoptosis
Besides proliferation, the influence of DOX treatment on
apoptosis was quantified with a polyclonal antibody against
cleaved Caspase-3 (Fig. 4F, 5A). Caspase-3 is one of the key
executioners of apoptosis [26]. The expression of cleaved
Caspase-3 protein was significantly increased at day 1 and
2, at the beginning of DOX-induced morphological damage.
At day 3, during severe morphological damage, and day 7,
during regeneration, expression of cleaved caspase-3 was
comparable to control level. Increased apoptosis at day 1
and 2 was primarily located along the crypt axis (Fig. 5B
showing day 1 after MTX treatment))
Effect of high-dose DOX treatment
on TCF-4 protein expression
To gain insight into the effects of DOX on the epithelial stem
cell compartment, the expression of TCF-4 was quantified.
TCF-4 is a transcription factor of the Wnt-signaling pathway
and is expressed in the gut epithelium in a gradient fashion
that is highest at the base of the crypts [1, 19]. TCF-4 − / −
mice lose the intestinal epithelial progenitor and stem cell
population before crypt formation can be established [17].
Therefore, TCF-4 has a role in intestinal epithelial stem cell
maintenance. The TCF-4 expression (Figs. 4F and 6) re-
mained very stable despite DOX treatment. Only at day 1
the TCF-4 expression increased significantly, although little
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Fig. 3 Effect of high-dose DOX treatment on the goblet-specific TFF3
expression in the small intestine. Immunohistochemical staining of the
goblet cell-specific protein TFF3 (A–E). TFF3 expression of the je-
junum of a control mouse (A), at day 1 (B), at day 2 (C), at day 3
(D) and at day 7 (E). In the control situation, TFF3 was expressed
in all goblet cells in the crypts and villi, at day 1 (B), the amount of
goblet cells expressing TFF3 maintained at control level. At day 2 (C),
TFF3 expression decreased visibly, the goblet cells localized in the
crypts showed no staining. At day 3 (D), during severe morphological
damage, TFF3 expression of goblet cells in the crypt was reconsti-
tuted. TFF3 expression at day 7 (E) was regenerated and comparable
to control situation. TFF3 protein expression levels were analyzed by
dot-blot technique, the TFF3 expression of control mice was set at
100% (F). TFF3 expression decreased significantly at day 1 and day
2, the expression was decreased to 50% of control level. During severe
morphological damage at day 3, the TFF3 expression increased almost
to control level. Day 7 showed TFF3 expression even above control
level. ∗P < 0.05 day 1 and 2 versus control. The bars are expressed in
mean + SEM
in absolute sense. But at day 2, day 3 and day 7, the TCF4
protein expression remained at control level.
Effect of high-dose DOX treatment on expression of
Bone morphogene 4 (BMP4)
To examine the role of BMP4 signaling in intestinal home-
ostasis the expression of BMP4 was quantified. BMP4 is
crucial for epithelial-mesenchymal cross-talk and intestinal
homeostasis. BMP4 is expressed in the intravillus and in-
tracrypt mesenchymal cells [8, 10], inhibition of BMP sig-
naling causes intestinal architectural abnormalities [8] and
decreased differentiation as seen in tumorigenesis [27].
BMP4 protein expression showed a mild decrease in ex-
pression level at day 1 after DOX treatment (Figs. 4F, 7A).
At day 2, this decrease in BMP4 expression level progressed
and was almost significant (P = 0.05) in comparison to the
control level. Thereafter, BMP4 day 2 but not to control.
Day 7 showed a non-significant decrease in expression com-
pared to control mice. BMP4 was predominantly expressed
in the intravillus mesenchym as shown by immunohisto-
chemistry (Fig. 7B, C), both in control as in MTX-treated
mice.
Discussion
This study revealed that DOX, in a dose of 10 and 6 mg/kg
induced severe morphological damage to the small intes-
tine of mice within 3 days, which was almost completely
regenerated by day 7. Moreover, it revealed that the intes-
tine was virtually not or much less affected by lower doses
of DOX. Mucositis induced by the chosen dose of DOX
was characterized by an increasing degree of intestinal mor-
phological damage at day 1 and 2, which correlated with a
significant increase in both apoptosis and proliferation. Dur-
ing this phase of epithelial hyper-proliferation, the epithelial
cells lost their highly differentiated status as measured by a
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Fig. 4 Effect of high-dose DOX treatment on epithelial proliferation.
The localization of epithelial proliferation was visualized by detection
of BrdU incorporation. BrdU incorporation of the jejunum of a control
mouse (A) and mice at day 1 (B), at day 2 (C), at day 3 (D) and at
day 7 (E). At day 1, the BrdU-positive cells were slightly migrated
upwards in the crypt, at day 2 the BrdU-positive cells were seen along
the entire length of the crypts. At day 3 the BrdU expression decreased
and showed a scattered pattern on some crypts and villi. The location of
BrdU-positive cells at day 7 was confined again to the lower part of the
crypts. PCNA, Caspase-3, TCF4 and BMP4 protein expression levels
were analyzed by Western-blot technique (F), the PCNA expression of
control mice was set at 100% (G). The expression of PCNA protein
showed a non-significant trend of increased expression at day 1, and a
significant increase at day 2. PCNA expression at day 3 and 7 showed
a decreasing trend to around 20% of control level. ∗P < 0.05 day 1 and
2 versus control. The bars are expressed in mean + SEM
significant down-regulation of epithelial-specific SI at days
2–3. The decreased expression of TFF3 at days 1–2 could
be caused by a decrease in goblet cell differentiation, but on
the other hand, could also be the result of increased TFF3
secretion. At day 3, the time-point when intestinal dam-
age was most severe, the morphology was characterized by
severe villus atrophy, a significant rise in crypt length, ep-
ithelial flattening, crypt loss, inhibition of proliferation and
impaired epithelial differentiation. During morphological re-
generation, at day 7, proliferation started to return to control
level, and SI and TFF3 expression levels were normalized
again.
In order to be able to prevent or treat chemotherapy-
induced mucositis, it is essential to know if different cy-
tostatic drugs induce the same or different kinds of intestinal
damage. Potten et al. demonstrated that there is a general
tendency for antibiotics, like DOX, and radiation to damage
the lower cell positions in the crypt near or at the position
of the stem cells (position 4–6) [12]. Alkylating agents on
the other hand mainly damage cells at position 6–8. Anti-
metabolites like MTX and a microtubule dissociating agents
act on higher cell positions [9–11]. It is, however, unclear if
cytostatic drugs attacking at the lowest positions in the crypts
cause a different kind of damage than drugs damaging cells at
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Fig. 5 Effect of high-dose
DOX treatment on epithelial
apoptosis. Caspase-3 protein
expression of the control mice,
analyzed by Western-blot
technique (Fig 4F), was set at
100% (A). At day 1 and 2, the
Caspase-3 levels increased
significantly in comparison to
the control levels. At day 3,
during severe morphological
damage the caspase-3
expression maintained at control
level, the same was seen at day
7, during the regenerative phase.
The increase in apoptosis at day
1 is primarily located in the
crypt region (B). ∗P < 0.05 day
1 and 2 versus control. The bars
are expressed in mean + SEM.
→ indicates apoptotic cells
higher positions. If we compare the DOX-induced mucosi-
tis as studied presently with the well-characterized MTX-
induced mucositis [34, 38, 44–46, 48], then it is clear that
there are many similarities and few discrepancies between
the two. Although the two drugs affected cells of different
hierarchical height [12], they both caused apoptosis, villus
atrophy, epithelial flattening, crypt loss and a temporary loss
of SI expression and TFF3 expression [45, 46, 48]. Since
SI is involved in carbohydrate metabolism and TFF3 is in-
volved in mucosal repair [6, 22, 30, 42], these data suggest
impaired absorption and mucosal repair after DOX as well as
after MTX treatment. In contrast, both MTX [45] and DOX
hardly affect the expression of lysozyme by Paneth cells in
the crypts (data not shown).
Fig. 6 Effect of high-dose DOX treatment on TCF-4 protein expres-
sion. TCF-4 protein expression of control mice, analyzed by Western-
blot technique (Fig. 4F), was set at 100%. At day 1, TCF-4 protein
expression increased significantly. At day 2, day 3, and day 7, the TCF-
4 protein expression remained stable at control level. ∗P < 0.05 day 1
versus control. The bars are expressed in mean + SEM
Decreased levels of TFF3 after both DOX and MTX was
at the same time as epithelial hyper-proliferation [45, 48],
but changes in proliferation, induced by MTX treatment fol-
lowed a different time-line compared to DOX treatment.
MTX causes proliferation inhibition within 1 day, followed
by a period of hyper-proliferation during severe intestinal
damage [34, 45]. DOX treatment leads to immediate hyper-
proliferation (day 1 and 2) with subsequent inhibition of
proliferation during severe morphological damage (day 3).
Moreover, the cell-fate specific affect of MTX on goblet cells
causing goblet cells to accumulate in the crypt and at the top
of the villus [45, 46] was not seen after DOX treatment.
The reason for these discrepancies remains to be further in-
vestigated, but might be directly related to the difference in
topographical height (and thus status) of the cells vulnerable
to the two different drugs. Overall, however, the similari-
ties in intestinal responses after DOX or MTX treatment are
striking. This suggests that there may be common pathways
involved in intestinal damage and repair.
Historically, chemotherapy- or radiation-induced mucosi-
tis was believed to be solely due to damage to dividing epithe-
lial cells at the bottom of the crypts [20]. However, recently
it has become clear that other parts of the intestinal mucosa
and submucosa might also be involved [35, 36]. Here we pro-
vide evidence for a mesenchymal contribution to the dam-
age by showing that BMP4, a very important lamina propria
derived-morphogen in the small intestine [8, 10], is affected
by DOX treatment. BMP4 was modulated by DOX during the
onset of damage at days 1 and 2. BMP4 expression decreased
almost significant at day 2, which correlated well with an in-
creasing degree of morphological damage, increased prolif-
eration, and loss of epithelial differentiation as measured by
the decreased SI and likely TFF3 expression. Very recently,
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Fig. 7 Effect of high-dose DOX treatment on expression of the mor-
phogen BMP4. The BMP4 protein expression of the control mice,
analyzed by Western-blot technique (Fig. 4F), was set at 100% (A).
Expression of the morphogen BMP4 protein showed a decreasing trend
at day 1, which was at the brink of significance (P = 0.05) at day 2
in comparison to control expression. At day 3, the BMP4 expression
showed an increasing trend. This increase in expression was signifi-
cant in comparison to day 2. Day 7 showed a decrease in expression
again beneath the level of control expression. The localization of BMP4
expression did not change at day three (C) in comparison to control sit-
uation (B). ∗P < 0.05 day 2 versus control, ∗∗P < 0.05 day 2 versus
day 3. The bars are expressed in mean + SEM
a link between the BMP and the Wnt pathways has been
demonstrated. It was shown that BMP signaling suppresses
Wnt signaling to ensure a balanced control of stem cell pro-
liferation and subsequent epithelial differentiation [8, 10].
Here we show that there indeed might be a close relationship
between BMP and Wnt pathways, because at day 1 when
BMP4 expression is decreased, expression of TCF4, a Wnt
effector, increased significantly, which correlated well with
increased proliferation and inhibited epithelial differentia-
tion. At day 2, BMP4 remained low, whereas TCF4 returned
to a normal level and remained at control level during the
following days. At day 3, when damage was most severe,
BMP4 was increased, which inversely correlated with pro-
liferation, and correlated with epithelial differentiation, as
suggested by the recovery of TFF3 expression level.
BMP is involved in epithelial-mesenchymal signaling
[8] and therefore we conclude that the data presented in
this study indicate that epithelial-mesenchymal cross-talk is
modulated during onset of DOX-induced damage in order to
stimulate proliferation instead of differentiation and during
severe intestinal damage to induce differentiation and inhibit
proliferation. During the regenerative phase, at day 7, BMP4
expression level was down-regulated again, which could be
a response to the shortage in number of crypts, since a block-
age of BMP4 has been shown to cause stem cells to divide,
leading to newly formed crypts [8, 10]. Therefore, our find-
ings are in line with the roles of the BMP and Wnt/TCF
pathway in epithelial homeostasis/morphogenesis. Further-
more, the decrease in BMP4 might also indirectly cause the
observed decrease in SI expression, because inhibition of
BMP4 stimulates Wnt signaling, and Wnt signaling itself
induces SOX9, a negative regulator of Cdx2, which is a SI
transcriptional activator [3, 10, 39]. In addition, BMP4 has
been shown to be directly involved in HNF-1α expression,
also a well-known activator of SI transcription [25]. Thus,
the decrease in BMP4 might result in a decrease in Cdx2 and
HNF-1α expression, two of the most important activators
of SI transcription [39]. Currently, it is not known whether
the Wnt or BMP4 signaling pathways regulate TFF3 gene
expression.
In conclusion, high-dose DOX induces severe damage to
the epithelium, which closely resembles damage induced by
MTX, indicating that general mechanisms of damage and
repair are involved. We show that signaling pathways in-
volving BMP4 and TCF4 and thus epithelial-mesenchymal
cross-talk are modulated by DOX-induced damage in such
a way that homeostasis of the progenitor compartment is
restored by initially inducing cell proliferation and inhibit-
ing differentiation and subsequently inducing differentiation,
inhibiting proliferation and promoting crypt fission. Under-
standing these mechanisms is essential to develop clinical
strategies to prevent chemotherapy-induced mucositis.
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